Cancer in children and adolescents is rare and accounts for only a minority of all cancers worldwide. Thanks to international cooperation and better risk stratification, contemporary multimodal treatment strategies have resulted in considerably improved cure rates over the last decades, with 80% of the children with cancer becoming long-term survirors. Despite these major advancements, the survival rates did not significantly improve for some pediatric cancers and can vary widely depending on the cancer type. Furthermore, with increasing numbers of childhood cancer survivors, long-term toxicity and the impact on quality-of-life has become an important problem to address. Novel strategies are needed to improve outcomes of pediatric cancer patients by increasing cure rates and reducing treatment-related side effects.

The mission of our lab is to improve outcomes and long-term quality-of-life of children diagnosed with cancer, through clinical-translational laboratory research, participating in clinical studies and collecting relevant biomaterials (biobanking)


The unit is headed by Prof. Dr. Tim Lammens

This research can be divided in several topics:


Acute Myeoloid Leukemia (AML)

Juvenile Myelomonocytic Leukemia (JMML)

Acute Lymphocytic Leukemia


Relapse refractory and high risk

Liquid biopsis, biobanking and clinical studies

Clinical studies in the field of pediatric oncology